Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) insider Ariel Hurley sold 3,203 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total value of $296,661.86. Following the completion of the transaction, the insider now owns 18,270 shares of the company's stock, valued at $1,692,167.40. This trade represents a 14.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Ariel Hurley also recently made the following trade(s):
- On Monday, January 13th, Ariel Hurley sold 2,250 shares of Blueprint Medicines stock. The shares were sold at an average price of $100.00, for a total value of $225,000.00.
- On Thursday, December 12th, Ariel Hurley sold 1,819 shares of Blueprint Medicines stock. The shares were sold at an average price of $93.26, for a total value of $169,639.94.
Blueprint Medicines Stock Down 1.6 %
NASDAQ:BPMC traded down $1.42 on Friday, reaching $87.12. The stock had a trading volume of 908,608 shares, compared to its average volume of 1,021,582. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. The company has a 50-day moving average of $99.43 and a 200 day moving average of $94.27. The stock has a market cap of $5.57 billion, a P/E ratio of -80.67 and a beta of 0.62. Blueprint Medicines Co. has a 12-month low of $80.68 and a 12-month high of $121.90.
Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, research analysts predict that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.
Wall Street Analyst Weigh In
BPMC has been the subject of several analyst reports. Piper Sandler boosted their price target on Blueprint Medicines from $109.00 to $119.00 and gave the company a "neutral" rating in a report on Monday, January 27th. HC Wainwright reiterated a "buy" rating and issued a $135.00 price target on shares of Blueprint Medicines in a report on Friday, February 14th. Stephens reiterated an "overweight" rating and issued a $140.00 price target on shares of Blueprint Medicines in a report on Thursday, January 2nd. StockNews.com downgraded Blueprint Medicines from a "hold" rating to a "sell" rating in a report on Monday, March 3rd. Finally, JMP Securities restated a "market outperform" rating and set a $125.00 price objective on shares of Blueprint Medicines in a report on Friday, February 14th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $125.21.
Check Out Our Latest Report on Blueprint Medicines
Hedge Funds Weigh In On Blueprint Medicines
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Blueprint Medicines by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 6,774,884 shares of the biotechnology company's stock valued at $590,905,000 after buying an additional 91,450 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Blueprint Medicines by 5.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,679,089 shares of the biotechnology company's stock worth $495,331,000 after purchasing an additional 291,822 shares in the last quarter. Wellington Management Group LLP grew its stake in Blueprint Medicines by 8.0% in the fourth quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company's stock worth $373,421,000 after purchasing an additional 316,754 shares in the last quarter. State Street Corp grew its stake in Blueprint Medicines by 16.2% in the third quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company's stock worth $255,827,000 after purchasing an additional 385,818 shares in the last quarter. Finally, William Blair Investment Management LLC grew its stake in Blueprint Medicines by 16.1% in the fourth quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company's stock worth $169,616,000 after purchasing an additional 269,896 shares in the last quarter.
Blueprint Medicines Company Profile
(
Get Free Report)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Further Reading
Before you consider Blueprint Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Blueprint Medicines wasn't on the list.
While Blueprint Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
